Stay updated on Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page
- Check6 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedRevision badge updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedMinor site revision update to v3.4.2 from v3.4.1; no changes to study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedThe page now displays Revision: v3.4.1 and no longer displays Revision: v3.4.0.SummaryDifference0.1%

- Check64 days agoChange DetectedA glossary toggle was added; QC-related metadata labels were updated to display 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0', replacing the previous labels.SummaryDifference0.3%

- Check71 days agoChange DetectedThe page revision was updated from v3.3.3 to v3.3.4. No study content or critical information appears to have changed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.